These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15087405)

  • 1. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.
    Zippelius A; Batard P; Rubio-Godoy V; Bioley G; Liénard D; Lejeune F; Rimoldi D; Guillaume P; Meidenbauer N; Mackensen A; Rufer N; Lubenow N; Speiser D; Cerottini JC; Romero P; Pittet MJ
    Cancer Res; 2004 Apr; 64(8):2865-73. PubMed ID: 15087405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
    von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
    Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.
    Anichini A; Molla A; Mortarini R; Tragni G; Bersani I; Di Nicola M; Gianni AM; Pilotti S; Dunbar R; Cerundolo V; Parmiani G
    J Exp Med; 1999 Sep; 190(5):651-67. PubMed ID: 10477550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes.
    Labarriere N; Pandolfino MC; Raingeard D; Le Guiner S; Diez E; Le Dréan E; Dreno B; Jotereau F
    Int J Cancer; 1998 Oct; 78(2):209-15. PubMed ID: 9754654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
    Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
    Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues.
    Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L
    Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype.
    D'Souza S; Rimoldi D; Líenard D; Lejeune F; Cerottini JC; Romero P
    Int J Cancer; 1998 Dec; 78(6):699-706. PubMed ID: 9833762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
    Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
    J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
    Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
    Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
    Mackensen A; Meidenbauer N; Vogl S; Laumer M; Berger J; Andreesen R
    J Clin Oncol; 2006 Nov; 24(31):5060-9. PubMed ID: 17075125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
    Pittet MJ; Valmori D; Dunbar PR; Speiser DE; Liénard D; Lejeune F; Fleischhauer K; Cerundolo V; Cerottini JC; Romero P
    J Exp Med; 1999 Sep; 190(5):705-15. PubMed ID: 10477554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
    Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; Liénard D; Cerottini JC; Romero P; Rufer N
    J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
    Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
    Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.
    Derré L; Bruyninx M; Baumgaertner P; Devevre E; Corthesy P; Touvrey C; Mahnke YD; Pircher H; Voelter V; Romero P; Speiser DE; Rufer N
    J Immunol; 2007 Aug; 179(4):2368-79. PubMed ID: 17675498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay.
    Griffioen M; Borghi M; Schrier PI; Osanto S
    Int J Cancer; 2001 Aug; 93(4):549-55. PubMed ID: 11477559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
    Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC
    Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma.
    Meidenbauer N; Zippelius A; Pittet MJ; Laumer M; Vogl S; Heymann J; Rehli M; Seliger B; Schwarz S; Le Gal FA; Dietrich PY; Andreesen R; Romero P; Mackensen A
    Cancer Res; 2004 Sep; 64(17):6319-26. PubMed ID: 15342421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Lejeune F; Speiser D; Rimoldi D; Cerundolo V; Dietrich PY; Cerottini JC; Romero P
    J Immunol; 2000 Jul; 165(1):533-8. PubMed ID: 10861093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.